UNIV TX SW MEDCTR is a generic drug manufacturer focused on Oncology, Neurology.
UNIV TX SW MEDCTR's Key Drugs
UNIV TX SW MEDCTR's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
UNIV TX SW MEDCTR's Recent FDA Approvals
New NDA/BLA approvals for UNIV TX SW MEDCTR over the last two years — novel drugs only, excluding generics and label supplements.
UNIV TX SW MEDCTR's Therapeutic Areas
UNIV TX SW MEDCTR's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
UNIV TX SW MEDCTR's Top Competitors
UNIV TX SW MEDCTR's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
UNIV TX SW MEDCTR Pipeline Snapshot
Active clinical trials for UNIV TX SW MEDCTR across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2019-11-01
- Latest
- 2020-02-06
- Applications
- 2